Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Exclusion Criteria

• •History of severe, life-threatening or other significant sensitivity to any drug.
• •Females who are or plan to become pregnant or breastfeeding or males whose partner is pregnant or planning to become pregnant.
• •Recent history of drug or alcohol abuse that could preclude adherence to the protocol.
• •Positive test result for hepatitis B surface antigen or anti-human immunodeficiency virus (HIV) antibodies.
• •Any current or past clinical evidence of cirrhosis (e.g., ascites, esophageal varices), or a liver biopsy or FibroTest/aspartate aminotransferase to platelet ratio (APRI) or FibroScan® showing cirrhosis or extensive bridging fibrosis.